EE200300363A - N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks - Google Patents

N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks

Info

Publication number: EE200300363A
Authority: EE; Estonia
Prior art keywords: pyridinyl; indole; medicament; diseases; manufacture
Prior art date: 2001-02-15

Application number

EEP200300363A

Other languages

English (en)

Estonian (et)

Inventor

P. Smith Craig

P. Rathbone Michel

Petty Margaret

Rampe David

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-15

Filing date

2002-02-14

Publication date

2003-10-15

2002-02-14 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2003-10-15 Publication of EE200300363A publication Critical patent/EE200300363A/xx

Links

102000006386 Myelin Proteins Human genes 0.000 title 1
108010083674 Myelin Proteins Proteins 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
210000005012 myelin Anatomy 0.000 title 1
JULKLMOOTJHVHH-UHFFFAOYSA-N n-pyridin-2-ylindol-1-amine Chemical class C1=CC2=CC=CC=C2N1NC1=CC=CC=N1 JULKLMOOTJHVHH-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

EEP200300363A 2001-02-15 2002-02-14 N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks EE200300363A (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26884601P	2001-02-15	2001-02-15
GBGB0119435.6A GB0119435D0 (en)	2001-02-15	2001-08-09	Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (fr)	2001-02-15	2002-02-14	Methode destinee au traitement de pathologies ou de troubles lies a la demyelinisation

Publications (1)

Publication Number	Publication Date
EE200300363A true EE200300363A (et)	2003-10-15

Family

ID=23024747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300363A EE200300363A (et)	2001-02-15	2002-02-14	N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks

Country Status (39)

Country	Link
US (10)	US6967210B2 (fr)
EP (1)	EP1368031A2 (fr)
JP (3)	JP2004518711A (fr)
KR (3)	KR100951542B1 (fr)
CN (2)	CN100522164C (fr)
AP (1)	AP1749A (fr)
AR (1)	AR035750A1 (fr)
AU (3)	AU2002247200B9 (fr)
BR (1)	BR0207272A (fr)
CA (1)	CA2438712A1 (fr)
CO (1)	CO5390085A1 (fr)
CR (1)	CR7023A (fr)
CZ (1)	CZ20032172A3 (fr)
EA (2)	EA012409B1 (fr)
EC (1)	ECSP024218A (fr)
EE (1)	EE200300363A (fr)
GB (1)	GB0119435D0 (fr)
HK (1)	HK1080361B (fr)
HR (1)	HRP20030652A2 (fr)
HU (1)	HUP0303203A3 (fr)
IL (2)	IL157341A0 (fr)
MA (1)	MA26152A1 (fr)
ME (1)	MEP21208A (fr)
MX (1)	MXPA03006110A (fr)
MY (1)	MY157745A (fr)
NO (1)	NO20033622L (fr)
NZ (4)	NZ527011A (fr)
OA (1)	OA12549A (fr)
PA (1)	PA8540101A1 (fr)
PE (1)	PE20040175A1 (fr)
PL (1)	PL363638A1 (fr)
SG (1)	SG134170A1 (fr)
SK (1)	SK10392003A3 (fr)
TR (4)	TR200800692T2 (fr)
TW (1)	TWI325319B (fr)
UA (2)	UA80394C2 (fr)
WO (1)	WO2002064126A2 (fr)
YU (1)	YU62903A (fr)
ZA (1)	ZA200306124B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions
CA2510292A1 (fr) *	2002-12-20	2004-07-15	Dynogen Pharmaceuticals, Inc.	Methodes de traitement de troubles de la vessie non douloureux au moyen de modulateurs du canal calcique de la sous unite ?<sb>2</sb>?
AU2004207010A1 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using sodium channel modulators
KR100742001B1 (ko) *	2003-03-21	2007-07-23	다이노젠 파마세우티컬스, 인코포레이티드	평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
GT200500063A (es) *	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) *	2005-04-28	2005-06-22	Paradigm Therapeutics Ltd	Ion channel
FR2892022B1 (fr) *	2005-10-19	2008-01-04	Urogene Sa	Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) *	2005-10-19	2008-01-04	Urogene	Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) *	2006-06-16	2013-04-16	Landon C. G. Miller	Compositions and methods for regulating membrane potential
DE102008044844B4 (de) *	2008-08-28	2018-08-30	Siemens Healthcare Gmbh	Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) *	2010-03-26	2018-05-31	가부시키가이샤 한도오따이 에네루기 켄큐쇼	반도체 장치
US20130184316A1 (en) *	2010-07-15	2013-07-18	Andrew Hornstein	Methods for diagnosing and treating concussive disorders
EP2667869A1 (fr) *	2011-01-28	2013-12-04	Acorda Therapeutics, Inc.	Utilisation d'inhibiteurs des canaux potassiques dans le traitement d'une paralysie cérébrale
TWI592156B (zh) *	2011-10-04	2017-07-21	艾可達醫療公司	使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
WO2019126643A1 (fr) *	2017-12-22	2019-06-27	Massachusetts Institute Of Technology	Compositions et méthodes de thérapie du syndrome de williams (sw)
EP4281118A4 (fr) *	2021-01-20	2025-01-01	Rush University Medical Center	Traitement amélioré pour la leucodsytrophie à cellules globoïdes ou la maladie de krabbe

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4970218A (en) *	1987-04-24	1990-11-13	Hoechst-Roussel Pharmaceuticals Inc.	N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) *	1987-04-24	1989-11-14	Hoechst-Roussel Pharmaceuticals, Inc.	N-(pyridinyl)-1H-indol-1-amines
DE3852335T2 (de) *	1987-04-24	1995-05-11	Hoechst Roussel Pharma	N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel.
DK0415103T3 (da) *	1989-08-02	1995-06-19	Hoechst Roussel Pharma	2,3-Dihydro-1-(pyridinylamino)-indoler, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
US5214038A (en) *	1991-04-15	1993-05-25	Hoechst-Roussel Pharmaceuticals Inc.	1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) *	1993-07-29	1995-02-02	Boehringer Ingelheim Kg	Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) *	1994-05-13	1995-10-17	Hoechst-Roussel Pharmaceuticals Inc.	Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) *	1994-11-08	1996-10-15	Muhlhauser; Mark A.	Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (fr) *	1995-03-10	1996-09-11	Boehringer Mannheim Gmbh	Procédé de fabrication d'un agent thérapeutique pour la régénération d'oligodendrocytes
FR2754147B1 (fr)	1996-10-03	2000-02-04	Mbh Technologies Sa	Installation et procede pour le traitement de carcasses
DK1056754T3 (da) *	1998-01-29	2004-02-16	Bristol Myers Squibb Co	Phosphatderivater af diaryl-1,3,4-oxadiazolon
US6544976B1 (en) *	1999-07-09	2003-04-08	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions

2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
2002
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active Expired - Fee Related
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Ceased
- 2002-02-14 CA CA002438712A patent/CA2438712A1/fr not_active Abandoned
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/fr not_active Ceased
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 EP EP02714974A patent/EP1368031A2/fr not_active Withdrawn
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active Expired - Fee Related
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
2005
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned

Also Published As

Publication number	Publication date
WO2002064126A2 (fr)	2002-08-22
JP2009185045A (ja)	2009-08-20
HRP20030652A2 (en)	2005-06-30
US7230015B2 (en)	2007-06-12
CN1529598A (zh)	2004-09-15
MEP21208A (en)	2010-06-10
AP1749A (en)	2007-06-13
US20090281147A1 (en)	2009-11-12
NO20033622L (no)	2003-10-06
NZ544720A (en)	2007-08-31
GB0119435D0 (en)	2001-10-03
CO5390085A1 (es)	2004-04-30
NZ556697A (en)	2009-01-31
JP2004518711A (ja)	2004-06-24
KR20090005254A (ko)	2009-01-12
KR100951542B1 (ko)	2010-04-09
ZA200306124B (en)	2004-11-08
US20090209595A1 (en)	2009-08-20
IL157341A0 (en)	2004-02-19
US7179821B2 (en)	2007-02-20
CA2438712A1 (fr)	2002-08-22
PA8540101A1 (es)	2003-09-05
UA80394C2 (en)	2007-09-25
SG134170A1 (en)	2007-08-29
US20090270458A1 (en)	2009-10-29
AU2002247200B9 (en)	2008-07-10
US6967210B2 (en)	2005-11-22
MY157745A (en)	2016-07-15
TR200800692T2 (tr)	2008-03-21
NZ539159A (en)	2006-11-30
US20060025452A1 (en)	2006-02-02
EP1368031A2 (fr)	2003-12-10
AR035750A1 (es)	2004-07-07
OA12549A (en)	2006-06-05
TR200800691T2 (tr)	2008-03-21
IL157341A (en)	2010-11-30
KR100951540B1 (ko)	2010-04-09
EA200600896A1 (ru)	2006-08-25
PE20040175A1 (es)	2004-03-29
US20040157889A1 (en)	2004-08-12
PL363638A1 (en)	2004-11-29
US20040157888A1 (en)	2004-08-12
HK1080361A1 (zh)	2006-04-28
US7534803B2 (en)	2009-05-19
NO20033622D0 (no)	2003-08-14
EA011319B1 (ru)	2009-02-27
BR0207272A (pt)	2004-02-10
AU2008201179A1 (en)	2008-04-03
MXPA03006110A (es)	2005-07-01
CR7023A (es)	2003-11-17
YU62903A (sh)	2006-05-25
WO2002064126A3 (fr)	2003-02-20
TR200301330T2 (tr)	2004-12-21
TR200800693T2 (tr)	2008-07-21
AU2008201179B2 (en)	2009-08-20
JP2010120958A (ja)	2010-06-03
US20050159456A1 (en)	2005-07-21
CN1679564A (zh)	2005-10-12
SK10392003A3 (sk)	2004-01-08
TWI325319B (en)	2010-06-01
MA26152A1 (fr)	2004-07-01
US20050234105A1 (en)	2005-10-20
ECSP024218A (es)	2003-09-24
AP2003002834A0 (en)	2003-09-30
HK1080361B (zh)	2009-10-30
KR20090005255A (ko)	2009-01-12
KR20040014459A (ko)	2004-02-14
NZ527011A (en)	2005-07-29
HUP0303203A2 (hu)	2003-12-29
EA200300882A1 (ru)	2003-12-25
AU2002247200B2 (en)	2007-12-13
CZ20032172A3 (cs)	2004-01-14
EA012409B1 (ru)	2009-10-30
CN100522164C (zh)	2009-08-05
AU2009238332A1 (en)	2009-12-10
US20030105150A1 (en)	2003-06-05
US20090209594A1 (en)	2009-08-20
UA88773C2 (ru)	2009-11-25
HUP0303203A3 (en)	2007-11-28

Publication	Publication Date	Title
EE200300295A (et)	2003-10-15	Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EE200300212A (et)	2003-08-15	Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
EE200200274A (et)	2003-06-16	Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
EE200000253A (et)	2001-06-15	Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks
EE200300312A (et)	2003-10-15	Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
IL168279A (en)	2015-06-30	Use of liposomal and aminoglycoside composition to prepare a drug for the treatment or improvement of infection
DK1272207T3 (da)	2007-09-10	Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
EE05316B1 (et)	2010-08-16	Kristalliline antikolinergikum, meetod selle valmistamiseks ja selle kasutamine ravimi valmistamiseks
DE60336485D1 (de)	2011-05-05	Kombinationstherapie gegen hyperproliferative erkrankungen
ATE359784T1 (de)	2007-05-15	Topische nasenbehandlung mit desloratadin und mometason furoat
EE200200062A (et)	2003-04-15	Monoaminoksüdaasi inhibiitorite kasutamine ravimite valmistamiseks rasvumuse raviks
PT1605956E (pt)	2016-03-09	Administração de capsaicinóides para o tratamento da osteoartrite
PT1485127E (pt)	2011-09-07	Administração de agentes para o tratamento de inflamação
EE200200214A (et)	2003-06-16	Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
AR028426A1 (es)	2003-05-07	Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
EE200300311A (et)	2003-10-15	Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE05056B1 (et)	2008-08-15	IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nhtud ateroskleroosi ravimiseks ja/v?i ennetamiseks
NO20023448D0 (no)	2002-07-18	Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
EE200300139A (et)	2003-06-16	Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
WO2003008637A3 (fr)	2003-10-16	Utilisation du genotypage dans l'individualisation des therapies
EE200100553A (et)	2003-02-17	Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
EE05534B1 (et)	2012-04-16	IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
IL157144A0 (en)	2004-02-08	Use of flumazenil to produce a medicament for the treatment of cocaine dependency
NO20032006L (no)	2003-07-01	Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
PL375629A1 (en)	2005-12-12	1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence